Catalent to sell New Jersey facility (updated)

Catalent

14/10/2024 11:36

(Adds details in paragraphs 5,6 and background in paragraphs
2-4)
       Oct 14 (Reuters) - Catalent  CTLT.N  has agreed to sell
its oral drug development and small-scale manufacturing facility
in Somerset, New Jersey to private contract drug manufacturer
Ardena, the companies said on Monday.
    Catalent provides contract manufacturing services and
performs fill-finish work, which involves the sterile filling
and packaging of syringes and injection pens, for drugmakers
including Danish pharma major Novo Nordisk's  NOVOb.CO  drug
Wegovy.
    Novo Holdings, the investment firm that has a controlling
interest in Novo Nordisk, signed a $16.5 billion deal to buy
Catalent in February to boost Wegovy supply, with the deal
expected to close toward the end of this year.
    Catalent and Ardena did not disclose financial terms of the
deal, which is expected to close in early 2025.
    Ardena, a provider of drug development services, said the
facility will help boost its commercial production of oral
drugs. The FDA-approved Somerset facility employs about 200
scientists and technicians, Ardena said.

 (Reporting by Bhanvi Satija in Bengaluru; Editing by Anil
D'Silva and Vijay Kishore)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))